Ruxolitinib cream: uses, strength, evidence, and side effects

At a glance

U.S. status

Prescription (U.S.)

Jobs

Vitiligo repigmentation · Mild to moderate atopic dermatitis

Watch for

Carries the JAK-inhibitor class boxed warning even though topical absorption is low. Repigmentation takes months and needs continued use.

Access

Brand-only with a high list price; coverage often requires prior authorization and failed alternatives.

Forms and strengths

1.5% cream twice daily (Rx, brand only)

How to use it

Thin layer twice daily to affected areas up to 10% of body surface; vitiligo response is judged at 6 months and continues to improve with use.

Side effects and cautions

Application-site acne or itch
Nasopharyngitis
Rare systemic effects reflected in the class warning

Get advice first if

Class boxed warning on serious infections, cardiovascular events, clots, and malignancy from oral JAK inhibitors; topical absorption is low but the warning applies. Not for use with biologics or other JAK inhibitors.

Regulatory status

FDA-approved (2021 for atopic dermatitis, 2022 for vitiligo) prescription drug. Approved in the E.U. for vitiligo; availability elsewhere varies.

Sources on file

These links support the claims above. Reviewed September 1, 2026. Drug labels link to DailyMed searches so the current label is always one click away.